Gain Therapeutics Announces Proposed Public Offering
13 Junho 2024 - 5:44PM
Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq:
GANX) today announced that it is proposing to offer and sell,
subject to market conditions, shares of its common stock (or
pre-funded warrants in lieu thereof) in an underwritten public
offering. Gain expects to grant the underwriter a 30-day option to
purchase up to an additional 15% of the shares of common
stock and pre-funded warrants offered in the offering. All of the
securities are being offered by the Company.
Gain intends to use the net proceeds from the
offering to continue clinical and nonclinical development of its
lead product candidate GT-02287 for the treatment of
neurodegenerative diseases including GBA1 Parkinson’s disease and
for general corporate purposes. The final terms of the offering
will depend on market and other conditions at the time of pricing,
and there can be no assurance as to whether or when the offering
may be completed, or as to the actual size or terms of the
offering.
Titan Partners Group, a division of American
Capital Partners, is acting as sole bookrunner for the
offering.
The securities described above will be offered
pursuant to a shelf registration statement on Form S-3 (File No.
333-265061), which was previously filed with the Securities
and Exchange Commission (“SEC”) and became effective
on June 1, 2022. A preliminary prospectus supplement and
accompanying base prospectus relating to and describing the terms
of the offering will be filed with the SEC and will be
available on the SEC’s website located at http://www.sec.gov,
copies of which may be obtained, when available, for free by
contacting Titan Partners Group LLC, a division of American
Capital Partners, LLC, 4 World Trade Center, 29th Floor, New York,
New York 10007, by phone at (929) 833-1246 or by email at
prospectus@titanpartnersgrp.com.
The offering will be made only by means of a
prospectus. This press release does not constitute an offer to sell
or the solicitation of an offer to buy any of the securities
described herein, nor shall there be any sale of these securities
in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other
jurisdiction.
About Gain Therapeutics,
Inc.
Gain Therapeutics, Inc. is a clinical-stage
biotechnology company leading the discovery and development of next
generation allosteric therapies. Gain’s lead drug candidate
GT-02287 for the treatment of GBA1 Parkinson’s disease, is
currently being evaluated in a Phase 1 clinical trial.
Leveraging AI-supported structural biology,
proprietary algorithms, and supercomputer-powered physics-based
models, the company’s Magellan™ drug discovery platform can
identify novel allosteric binding sites on disease-implicated
proteins, pinpointing pockets that cannot be found or drugged with
current technologies. Its AI and machine-learning tools and virtual
screening capabilities leverage the emerging on-demand compound
libraries covering vast chemical spaces of over five trillion
compounds to identify and select suitable small molecule hits for
experimental validation.
Gain’s unique approach enables the discovery of
novel, allosteric small molecule modulators that can restore or
disrupt protein function. Deploying its highly advanced platform,
Gain is accelerating drug discovery and unlocking novel
disease-modifying treatments for untreatable or difficult-to-treat
disorders including neurodegenerative diseases, rare genetic
disorders and oncology.
Forward Looking Statements
This release contains “forward-looking
statements” made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These statements
are typically preceded by words such as “believes,” “expects,”
“anticipates,” “intends,” “will,” “may,” “should,” or similar
expressions. These forward-looking statements reflect management’s
current knowledge, assumptions, judgment and expectations regarding
future performance or events. Although management believes that the
expectations reflected in such statements are reasonable, they give
no assurance that such expectations will prove to be correct or
that those goals will be achieved, and you should be aware that
actual results could differ materially from those contained in the
forward-looking statements. Forward-looking statements are subject
to a number of risks and uncertainties, including, but not limited
to, risks associated with market conditions and the satisfaction of
customary closing conditions related to the offering and
uncertainties related to the Company’s expectations regarding the
completion, timing and size of the proposed offering. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to the Company’s business in
general, please refer to the Company’s prospectus supplement to be
filed with the SEC, and the documents incorporated by reference
therein, including the Company’s Form 10-K for the year ended
December 31, 2023 and Form 10-Q for the quarter ended March 31,
2024.
All forward-looking statements are expressly
qualified in their entirety by this cautionary notice. You are
cautioned not to place undue reliance on any forward-looking
statements, which speak only as of the date of this release. We
have no obligation, and expressly disclaim any obligation, to
update, revise or correct any of the forward-looking statements,
whether as a result of new information, future events or
otherwise.
Investor Contact: CORE IR(516)
222-2560ir@gaintherapeutics.com
Media Contacts:Russo PartnersNic Johnson and
Elio
Ambrosionic.johnson@russopartnersllc.comelio.ambrosio@russopartnersllc.com(212)
845-4242
Gain Therapeutics (NASDAQ:GANX)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Gain Therapeutics (NASDAQ:GANX)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024